Biogen Inc
NAS : BIIB$232.65+1.76%Oct 16 close
Financials
Consolidated Statements of Income
USD · reported units. Click a value to inspect its source.
| Reported line item | Jan 1, 2025 to Dec 31, 2025 (current) | Jan 1, 2024 to Dec 31, 2024 | Jan 1, 2023 to Dec 31, 2023 |
|---|---|---|---|
| Revenues | |||
| Cost of sales, excluding amortization and impairment of acquired intangible assets | |||
| Research and development | |||
| Acquired in-process research and development, upfront and milestone expense | |||
| Selling, general and administrative | |||
| Amortization and impairment of acquired intangible assets | |||
| Collaboration profit sharing/(loss reimbursement) | |||
| (Gain) loss on fair value remeasurement of contingent consideration | |||
| Impairment of ROU asset | |||
| Restructuring charges | |||
| Gain on sale of priority review voucher, net | |||
| Other (income) expense, net | |||
| Total cost and expense | |||
| Income before income tax (benefit) expense | |||
| Income tax (benefit) expense | |||
| Net income | |||
| Net income attributable to noncontrolling interests, net of tax | |||
| Net income attributable to Biogen Inc. | |||
| Basic earnings per share attributable to Biogen Inc. (in dollars per share)USD / share | |||
| Diluted earnings per share attributable to Biogen Inc. (in dollars per share)USD / share | |||
| Weighted-average number of common shares outstanding (in shares)Shares | |||
| Diluted earnings per share attributable to Biogen Inc. (in shares)Shares |
22 line items · 3 reported periodsOriginal filing order · parentheses indicate negative amounts
Each column reflects this filing’s presentation. Original line items and period dates are preserved.